Clinical trials: Daratumumab
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This single-arm, open-label phase II study aim to evaluate the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) combined with Rituximab in ITP patients.This study will be conducted in ITP patients who had not…
- Trial name
- NCT07362199
- Testing
- Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd)…
- Trial name
- Iber-KDd (NCT05896228)
- Testing
- Iberdomide, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benjamin T Diamond, MD
Plasma Cell Myeloma
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and…
- Trial name
- IMROZ (NCT03319667)
- Testing
- Isatuximab SAR650984, Bortezomib, Lenalidomide
- Where
- 104 sites in United States, Australia and 19 more
- Volunteers
- 475 people
- Sponsor
- Sanofi
Multiple Myeloma
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Japanese participants with…
- Trial name
- DREAMM 7 (NCT06868667)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 16 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment…
- Trial name
- NCT00574288
- Testing
- Part 1: Daratumumab, Part 2: Daratumumab, Methylprednisolone
- Where
- 7 sites in United States, Denmark and 2 more
- Volunteers
- 104 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation…
- Trial name
- NCT06932562
- Testing
- Linvoseltamab, Daratumumab, Lenalidomide
- Where
- 59 sites in Australia, Austria and 16 more
- Volunteers
- 1,000 people
- Sponsor
- European Myeloma Network B.V.
Multiple Myeloma
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with daratumumab in participants with relapsed refractory multiple myeloma (rrMM).
- Trial name
- NCT03221634
- Testing
- Pembrolizumab, Daratumumab
- Where
- 23 sites in United States, Canada and 4 more
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
The purpose of the study is to compare the efficacy and safety of daratumumab, lenalidomide and dexamethasone (DRd) to that of modified bortezomib, lenalidomide and dexamethasone (VRd-lite), in terms of progression-free survival…
- Trial name
- NCT06497738
- Where
- 6 sites in China
- Volunteers
- 112 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Multiple Myeloma
Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex
The purpose of this study is to evaluate the effects of the addition of daratumumab to pomalidomide and dexamethasone in terms of progression-free survival in subjects with relapsed or refractory Multiple Myeloma.
- Trial name
- EMN14 (NCT03180736)
- Testing
- Daratumumab, Pomalidomide, Dexamethasone
- Where
- 40 sites in Belgium, Czechia and 8 more
- Volunteers
- 304 people
- Sponsor
- Stichting European Myeloma Network
Relapsed or Refractory Chronic Lymphocytic Leukemia
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
Ibrutinib, a first-in-class Bruton Tyrosine kinase (BTK) inhibitor, has become an established treatment in relapsed/refractory chronic lymphocytic leukemia (CLL).
- Trial name
- IDA53 (NCT03734198)
- Testing
- Ibrutinib, Daratumumab
- Where
- 24 sites in France
- Volunteers
- 29 people
- Sponsor
- French Innovative Leukemia Organisation
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.
- Trial name
- NCT04264884
- Testing
- Daratumumab
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.
- Trial name
- NCT05137054
- Testing
- Linvoseltamab, Daratumumab, Carfilzomib
- Where
- 42 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Regeneron Pharmaceuticals
Hemophilia A With Inhibitor
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
To evaluate the time of response, sustained remission rate, and relapse rate of CD38 monoclonal antibody (Daratumumab) combined with SCT800 (rFVIII) in the treatment of hemophilia A adolescents and adults with high titer…
- Trial name
- NCT05888870
- Testing
- SCT800 and Daratumumab, SCT800
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Healthy
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
The purpose of this study is to assess the safety and tolerability of daratumumab following a single subcutaneous (SC) administration in healthy participants and to determine whether premedication with corticosteroids is required…
- Trial name
- NCT03320707
- Testing
- Daratumumab, rHuPH20
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Acute Kidney Injury, Multiple Myeloma
Biomarkers of AKI in Patients Receiving Daratumumab
The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with…
- Conditions
- Acute Kidney Injury, Multiple Myeloma, Light Chain Nephropathy
- Trial name
- NCT06549634
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Multiple Myeloma
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
- Trial name
- MajesTEC-2 (NCT04722146)
- Testing
- Teclistamab, Daratumumab, Pomalidomide
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
AL Amyloidosis
Daratumumab for the Treatment of Patients With AL Amyloidosis
Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month.
- Trial name
- NCT02841033
- Testing
- daratumumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Boston Medical Center
Multiple Myeloma
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with lenalidomide and dexamethasone, daratumumab and dexamethasone, or daratumumab, lenalidomide, and dexamethasone in treating…
- Trial name
- NCT06042725
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Multiple Myeloma in Relapse
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM).
- Trial name
- NCT04925193
- Testing
- Selinexor, Pomalidomide, Daratumumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Colorado, Denver
Newly Diagnosed Multiple Myeloma, Multiple Myeloma
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible…
- Conditions
- Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
- Trial name
- NCT06348147
- Testing
- Daratumumab, Lenalidomide, Bortezomib
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center